人克隆化LAK细胞对裸鼠人肺巨细胞癌细胞系模型的实验治疗

应用肿瘤病人外周血克隆化LAK细胞对裸鼠的人肺巨细胞癌细胞系高转移株(PLA801-D)模型进行实验治疗。结果表明,LAK细胞治疗组裸鼠14只平均活存天数118.3天,对照组12只平均活存88.8天,治疗组长于对照组,P<0.05。经LAK细胞治疗组有两例荷瘤裸鼠肿瘤消退。组织病理学观察,肿瘤细胞通过血行和淋巴转移于肺部和淋巴结,11例治疗组裸鼠中仅1例转移,而对照组裸鼠共观察8例中有4例发生转移,且1例除肺和淋巴结有转移外在心肌纤维间有广泛的肿瘤细胞转移。电镜观察,肿瘤细胞有超微结构的特点,部分细胞呈现凋亡的改变。本文对LAK细胞治疗的可能有效机理进行了初步探讨。

EXPERIMENTAL THERAPY OF HUMAN LUNG GIANT CELL CARCINOMA BY CLONAL HUMAN LAK CELLS IN NUDE MICE

The clonal human lymphokine activated killer (LAK) celis from PBL of cancer patients were used to treat nude mice inoculated with human lung giant celi carcinoma (PLA801-D). The results showed that the mean survival time (MST) of the 14 nude mice treated with clonal human LAK celis was longer than that of the 12 controlted ones. The MST were 118.3 days and 88.8 days respectively (P<0.05). The immunotherapeutic efficacy was evidenced by marked tumor regression in 2 treated nude mice. Under microscope it was found that the neoplastic cells through the blood vessels or lymphatic canals to metastasize to the lungs and lymph nodes. Especially, many tumor metastasis foci among the cardiac muscle fibrils and numerous lymph nodel were also observed in some of the controlled mice. By using transmission electronmicroscopy, the ultrastructural characteristics of this neoplastic cell line (PLA801-D) were analyzed. The morphological figures of apoptosis were also remarkable. The probable mechanism underlying the therapeutic efficacy of clonal LAK cells was discussed.